Answers are grounded in this paper and cite their sources.
Introduction Giant cell tumour of bone (GCTB) is a rare neoplasm that predominantly arises from the epiphysis of long bones. Surgical excision remains the gold standard for the management of GCTB. However, when GCTB originates from the sphenoid bone, complete surgical resection may be precluded due to the proximity of critical neural and vascular structures. The introduction of denosumab, a monoclonal antibody targeting RANKL, has provided an alternative therapeutic option for unresectable or surgically challenging cases. Given the rarity of sphenoid GCTB and the limited evidence regarding long-term medical management, detailed reports of prolonged treatment courses are essential to inform clinical practice. Case presentation and literature review In May 2018, a 16-year-old female patient presented with severe headache, dizziness, vomiting, double vision, and right-sided retrobulbar pain. Magnetic resonance imaging (MRI) of the brain revealed a large sellar mass invading the right cavernous sinus. Endocrine assessment confirmed severe panhypopituitarism, for which appropriate hormone replacement therapy was initiated. Four months later, a follow-up MRI demonstrated significant tumour progression, prompting surgical intervention. Histopathological evaluation confirmed the diagnosis of GCTB. Postopera-tively, denosumab was commenced, resulting in a 40% volume regression within 5 months. Denosumab was continued until December 2021; In this period to December, disease stability was maintained. The therapy was subsequently discontinued. In July 2022, follow-up MRI revealed marked tumour progression, prompting the resumption of denosumab. The patient currently receives 120 mg every 4 weeks, with consequent significant tumour regression. We conducted a systematic literature search resulting in 14 case reports of sphenoid GCTB with short-medium-term denosumab treatment. Conclusions Intracranial GCTBs, particularly those arising from the sphenoid bone, are rarely amenable to complete surgical resection, necessitating alternative therapeutic approaches. Overall, this case, to our knowledge, represents the longest reported duration of effective denosumab treatment for sphenoid GCTB to date, with sustained disease control over 7 years of therapy. It also demonstrates possible tumour progression in the event of cessation of denosumab therapy.
No takes yet. Share an insight, caveat, or question.
Stempler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: